KU-0063794

Catalog No.S1226

For research use only.

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

KU-0063794 Chemical Structure

CAS No. 938440-64-3

Selleck's KU-0063794 has been cited by 65 publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Other mTOR Products

Biological Activity

Description KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.
Targets
mTORC1 [1]
(Cell-free assay)
mTORC2 [1]
(Cell-free assay)
~10 nM ~10 nM
In vitro

Compared with the mTOR inhibitor PP242, KU-0063794 exhibits higher specificity for mTOR, as being inactive against PI3Ks or 76 other kinases. In HEK-293 cells, KU-0063794 at 30 nM is sufficient to rapidly ablate S6K1 activity by blocking the phosphorylation of the hydrophobic motif (Thr389) and subsequently the phosphorylation of the T-loop residue (Thr229). In case of IGF1 stimulation of serum-starved HEK-293 cells, 300 nM of KU-0063794 is needed to inhibit the S6K1 activity by ~90%. KU-0063794 at 100-300 nM also completely inhibits the amino-acid-induced phosphorylation of S6K1 and S6 protein. Similar to S6K1, KU-0063794 inhibits the phosphorylation of mTORC1 at Ser2448 and mTORC2 at Ser2481 in a dose-dependent and time-dependent manner. In the presence of serum or following IGF1 stimulation, KU-0063794 induces a dose-dependent inhibition of the activity and phosphorylation of Akt at Ser473 and unexpected Thr308 as well as the phosphorylation of the Akt substrates PRAS40 at Thr246, GSK3α/GSK3β at Ser21/Ser9 and Foxo-1/3a at Thr24/Thr32. KU-0063794 but not rapamycin inhibits SGK1 activity and Ser422 phosphorylation as well as its physiological substrate NDGR1 in a dose-dependent manner, to the same extent as S6K1 and Akt phosphorylation, whereas KU-0063794 dose not inhibit phorbol ester induced ERK or RSK phosphorylation and RSK activation. Compared with rapamycin, KU-0063794 exhibits more significant potency to induce the complete dephosphorylation of 4E-BP1 at Thr37, Thr46 and Ser65. KU-0063794 inhibits cell growth of both wild-type and mLST8-deficient MEFs and induces a G1 cell cycle arrest, more significantly than rapamycin. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2  MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVuwMlHjiJN3MNMg{txO NI\1Opc4OiCq M2XIdoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHHRZos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK3PFgyQSd-Mk[yO|g5OTl:L3G+
HepG2  MX\Dc4xwdnliRn;ycYF1cW:wIFHzd4F6 MonvNgKBmzVywrFOwG0> NEDpOXkyOCCm M4LY[YRm[3KnYYPld{B1cGViboXtZoVzKG:oII\pZYJt\SCKZYDHNkBkd2yxbnnld:Khe2mpbnnmbYNidnSueR?= NXPrZVBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yO|g5OTlpPkK2Nlc5QDF7PD;hQi=>
HepG2  NVO0SnVFSXCxcITvd4l{KEG|c3H5 NI[2VooxNjIkgKO1NOKh|ryP MmLlOFghcA>? NWKx[HdRcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ5OEixPUc,OjZ{N{i4NVk9N2F-
HepG2  MVnGeY5kfGmxbjDBd5NigQ>? MlXFOU8yOCEQvF2= MnXlNlQhcA>? M3jpfYRz[W2jdHnjZYxtgSCrbnjpZol1eyCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJIF1KFOncj20O|M> NXrqdnhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yO|g5OTlpPkK2Nlc5QDF7PD;hQi=>
HepG2  Ml\6SpVv[3Srb36gRZN{[Xl? NVrtNlREPS9zMDFOwG0> MX2yOEBp M2TIdIRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDITWYy|rFiYX7kJIN6[2yrbjDENeKh MmLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{N{i4NVkoRjJ4Mke4PFE6RC:jPh?=
HepG2  NUnWW29KTnWwY4Tpc44hSXO|YYm= MVKwMlHjiJN3MNMg{txO NYq4WXl3OjRiaB?= MX\pcoR2[2W|IIC2NkBld3ewcnXneYxifGmxbjygRoVkdGmwLUGg[ZhxemW|c3nvckBidmRiTFOzRk1KKHSxIFzDN2IuUUliY3;ueoVze2mxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFnybpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK3PFgyQSd-Mk[yO|g5OTl:L3G+
HepG3  NXXiSnNPTnWwY4Tpc44hSXO|YYm= M4r5PVAvOeLCk{WwxsDPxE1? MX20PEBp MUXpcoR2[2W|IHPlcIwh[XW2b4DoZYd6KGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFTtO4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK3PFgyQSd-Mk[yO|g5OTl:L3G+
AGS NFW2VXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXCfXhEUUN3ME2xOU4xKMLzIEKuPVEh|ryP NFq3eoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5O|Q4QCd-MkS1PVc1Pzh:L3G+
HGC27 M3e0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF3LkCgxtEhPC56MjFOwG0> M{TFXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm3OFc5Lz5{NEW5O|Q4QDxxYU6=
MKN45 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInadVdKSzVyPUCuPFIhyrFiMD6wNUDPxE1? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7N{S3PEc,OjR3OUe0O|g9N2F-
NUGC4 NYG3bGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPHTWM2OD1{LkmzJOKyKDBwM{Gg{txO MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7N{S3PEc,OjR3OUe0O|g9N2F-
PC9 NUL2fnVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfhO|IhcA>? MX\JR|UxRTFyLkG1xtExNjZ{IH7N MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
PC9GR NVjvNlMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXIZ2Y4OiCq MYHJR|UxRTZwMkJCtVEvOzBibl2= Ml;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{S4PFAoRjJ|OEe0PFgxRC:jPh?=
H1650 Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnxWmdMPzJiaB?= NVPDeIwzUUN3ME23MlYyyrFyLk[yJI5O NEiwb5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3OFg5OCd-MkO4O|Q5QDB:L3G+
H1975 M2nSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDUd2lRPzJiaB?= NEDicFJKSzVyPUGxMlE2yrFyLkmzJI5O M{TPN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEe0PFgxLz5{M{i3OFg5ODxxYU6=
PC9 MofHSpVv[3Srb36gRZN{[Xl? NW\uVHBSOTBwMUWgcm0> M2e4V|czKGh? NWPyOIs3cW6qaXLpeJMhdVSRUjDwbI9{eGixconsZZRqd25ic4TheJV{yqB? NIDobnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3OFg5OCd-MkO4O|Q5QDB:L3G+
PC9GR Mn;xSpVv[3Srb36gRZN{[Xl? NVPJR|FlPi5{MTDuUS=> MW[3NkBp Mm\QbY5pcWKrdIOgcXRQWiCyaH;zdIhwenmuYYTpc44he3SjdIXzxsA> NUXWSY9yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O|Q5QDBpPkKzPFc1QDhyPD;hQi=>
H1650 MknsSpVv[3Srb36gRZN{[Xl? NVyyVZgyPy54MTDuUS=> MoT4O|IhcA>? NITHc5VqdmirYnn0d{BuXE:UIIDoc5NxcG:{eXzheIlwdiC|dHH0eZPDqA>? Mkf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{S4PFAoRjJ|OEe0PFgxRC:jPh?=
H1975 MXXGeY5kfGmxbjDBd5NigQ>? NWroUHQ{OTFwMUWgcm0> M4P5S|czKGh? MmHSbY5pcWKrdIOgcXRQWiCyaH;zdIhwenmuYYTpc44he3SjdIXzxsA> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
PC9 MkS0SpVv[3Srb36gRZN{[Xl? MkTxNVAvOTVibl2= MWK3NkBp NHvGSVJqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YheDdyU{\L MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
PC9GR NHOxfotHfW6ldHnvckBCe3OjeR?= NEXVfms3NjJzIH7N MXm3NkBp NF\EPY9qdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YheDdyU{\L MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
H1650 MYHGeY5kfGmxbjDBd5NigQ>? NEXROFU4NjZzIH7N MlnCO|IhcA>? NInhZ4RqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YheDdyU{\L MlP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{S4PFAoRjJ|OEe0PFgxRC:jPh?=
H1975 NHTjdYpHfW6ldHnvckBCe3OjeR?= NXnjTGw1OTFwMUWgcm0> M2fUW|czKGh? NX34cGlHcW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKHB5MGO2Ty=> MniwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{S4PFAoRjJ|OEe0PFgxRC:jPh?=
LNCaP MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYiwMVExKM7:TR?= NUHnW4hIOjRiaNMg Mn;N[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NHHaT2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0NFYxPSd-MkO4OFA3ODV:L3G+
PC-3 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3qxO|AuOTBizszN MXmyOEBpyqB? NWnRXJRL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NHHjcXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0NFYxPSd-MkO4OFA3ODV:L3G+
MDA-MB-468  MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYLLO|RkOC1zMDFOwG0> MofDNlQhcMLi M4DIToRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2ME[wOUc,OjN6NEC2NFU9N2F-
LNCaP NHfGeJRHfW6ldHnvckBCe3OjeR?= MXGyNFDjiJN6MECgcm0> NWnmNlhwOjRiaNMg MkHY[IVkemWjc3XzJJRp\SCyaH;zdIhwenmuYYTpc44hdGW4ZXygc4YheDdyU{\LJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M3\NfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OESwOlA2Lz5{M{i0NFYxPTxxYU6=
PC-3 M3HyXGZ2dmO2aX;uJGF{e2G7 MWqyNFDjiJN6MECgcm0> NFHCcIozPCCqwrC= NHPBb3Fl\WO{ZXHz[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCuZY\lcEBw\iCyN{DTOmshcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NYPKc5RlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFA3ODVpPkKzPFQxPjB3PD;hQi=>
MDA-MB-468  Mnr4SpVv[3Srb36gRZN{[Xl? M3j4T|IxOOLCk{iwNEBvVQ>? NH:4NI8zPCCqwrC= MYLk[YNz\WG|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBt\X[nbDDv[kBxPzCVNlugbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MoPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEC2NFUoRjJ|OESwOlA2RC:jPh?=
Caki-1  NFzxbVdHfW6ldHnvckBCe3OjeR?= NYPMRnE2OTByLUKwNFAhdk1? MV:xNE0yQDBibXnu M3fl[GROW09? M2\JRYlvcGmkaYTzJIJwfGhibWTPVmMyKGGwZDDtWG9TSzJiYYOgbY5lcWOjdHXkJIJ6KHSqZTDk[YNz\WG|ZTDpckBxcG:|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCnZn\lZ5RwenN? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN2OUm4PUc,OjN|NEm5PFk9N2F-
786-O Mm\6SpVv[3Srb36gRZN{[Xl? MXqxNFAuOjByMDDuUS=> MWixNE0yQDBibXnu MYLEUXNQ MYXpcohq[mm2czDic5RpKG2WT2LDNUBidmRibWTPVmMzKGG|IHnu[Ilk[XSnZDDifUB1cGViZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1cW:wIH;mJIRwf26|dILlZY0h\W[oZXP0c5J{ NEjIR4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0PVk5QSd-MkOzOFk6QDl:L3G+
Caki-1  MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFK0eXA{ODBvNECwNEBvVQ>? MVOyOE06PiCq M3ns[2ROW09? M1rISpN2eHC{ZYPz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M4nFZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{S5PVg6Lz5{M{O0PVk5QTxxYU6=
786-O NGTBTHFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUHYNGVEOzByLUSwNFAhdk1? MmewNlQuQTZiaB?= NVvLUpJbTE2VTx?= M3zLRZN2eHC{ZYPz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVHRdW9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFk6QDlpPkKzN|Q6QTh7PD;hQi=>
Caki-1  MVvGeY5kfGmxbjDBd5NigQ>? M2rtTlIhyrWP NHvwcos4OiCq MVjEUXNQ M3HvNolv\HWlZYOgS|Eh[2WubDDjfYNt\SCjcoLld5Qh[W6mIHH1eI9xcGGpeR?= M3[3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{S5PVg6Lz5{M{O0PVk5QTxxYU6=
786-O M4rweGZ2dmO2aX;uJGF{e2G7 M4r6cVIhyrWP NFLnPIE4OiCq NF:yfoRFVVOR Mn\QbY5lfWOnczDHNUBk\WyuIHP5Z4xmKGG{cnXzeEBidmRiYYX0c5Bp[We7 NEjmXoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0PVk5QSd-MkOzOFk6QDl:L3G+
HEK293 NUT4W5ZFTnWwY4Tpc44h[XO|YYm= NEjrd2szKGi{cx?= M2LVVmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSmxCTy22YXfn[YQhdVSRUjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIXzbY5oKGKrb4Tpcplt[XSnZDDwO|BUPktic4Xid5Rz[XSnIHHmeIVzKDJiaILzJIJ6KGGucHjhd4Nz\WWwIHPvcZBmfGm2aX;uJIF{e2G7LDDJR|UxRTBwMECz{txO M1yxWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{[yNlM3Lz5zOUe2NlI{PjxxYU6=
HBCx-10 MYXGeY5kfGmxbjDhd5NigQ>? NGTk[3o2KG2pL3vn MYHQc5RmdnSrYYTpc44hd2ZiaYLpco91\WOjbj3pcoR2[2WmIIT1cY9zKHKnZ4Lld5Nqd25iYXfhbY5{fCCqdX3hckBJSkO6LUGwJINmdGy|IIjlco9oemGodHXkJIlvKGmvbYXuc4NwdXC{b33pd4VlKG2xdYPlJIF1KDVibXevb4ctKHCxIIHkJIFldWmwaYP0[ZJm\CCxbjDkZZl{KDFidH:gN{Bw\iC5ZXXrcJkh[3mlbHW= NYqwNJlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OlIzOzZpPkG5O|YzOjN4PD;hQi=>
U87MG NI\qT2dHfW6ldHnvckBie3OjeR?= MnfhNkBpenN? NGi3XodKdmirYnn0bY9vKG:oIH3UU3JEOSCrbjDoeY1idiCXOEfNS{Bk\WyuczDhd5Nme3OnZDDhd{BxcG:|cHjvdplt[XSnZDDTOkBzcWKxc3;tZYwheHKxdHXpckApW2W{MkO1M|I{PilibHX2[Ywh[W[2ZYKgNkBpenNiYomgW4V{fGW{bjDicI91fGmwZzygTWM2OD1yLkJOwG0> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzOkc,OTl5NkKyN|Y9N2F-
U87MG MULGeY5kfGmxbjDhd5NigQ>? MUiyJIhzew>? NHPMSmRKdmirYnn0bY9vKG:oIH3UU3JEOiCrbjDoeY1idiCXOEfNS{Bk\WyuczDhd5Nme3OnZDDhd{BxcG:|cHjvdplt[XSnZDDBT3QhMFOnckS3N{khdGW4ZXygZYZ1\XJiMjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yxiSVO1NF0xNjF3zszN M2jl[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{[yNlM3Lz5zOUe2NlI{PjxxYU6=
T47D M2rrNmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2i2TlEzOCCqcoO= NVf2OIdvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEGyNEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuN|XPxE1? NV7tTXU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OlIzOzZpPkG5O|YzOjN4PD;hQi=>
HEK293 NEn2XJBHfW6ldHnvckBie3OjeR?= M3vX[GlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSmxCTy22YXfn[YQhdVSRUjCoNVM3OiC2bzCyOVQ6MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMtKEmFNUC9NE4xODJ3zszN NX:3UY9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|U4QTNpPkKzN|c2Pzl|PD;hQi=>
MDA-MB-468 MY\GeY5kfGmxbjDhd5NigQ>? NYnpeFZyOiCqcoO= M3XLNmlvcGmkaYTpc44hd2ZibWTPVmMzKGmwIHj1cYFvKE2GQT3NRk01PjhiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiU3XyOFc{KGGodHXyJFIhcHK|LDDJR|UxRTBwMkVOwG0> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5NUe5N{c,OjN|N{W3PVM9N2F-
MDA-MB-468 NXy0R2RnTnWwY4Tpc44h[XO|YYm= MWSyJIhzew>? NFLpTJNKdmirYnn0bY9vKG:oIH3UU3JEOSCrbjDoeY1idiCPRFGtUWIuPDZ6IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBxWzZicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlI{PS9{M{[gZYZ1\XJiMjDodpMtKEmFNUC9NE43Ps7:TR?= MoXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|N{W3PVMoRjJ|M{e1O|k{RC:jPh?=
HEK293 M2nrOWZ2dmO2aX;uJIF{e2G7 NYGxZ3Z6OzBibXnudy=> NUTkb|lJUW6qaXLpeIlwdiCxZjDtWG9TSzFiaX6gTGVMOjl|IHPlcIx{KHW|aX7nJGdUXC22YXfn[YQhWz[NMTDvdkBCc3RzIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6|IHL5JIludXWwb3Lsc5R1cW6pIHHzd4F6NCCLQ{WwQVAvODIQvF2= NWjJPZRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNVE1QDBpPkK5NlEyPDhyPD;hQi=>
PC3 NHmyN2xHfW6ldHnvckBie3OjeR?= MlvjNVAxKG2pL3vn NGToenZKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gZZQhW2W{NEezJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIGDDN{Bk\WyuczD4[Y5w\3KjZoSgcY92e2VibX;k[Ywh[XRiMUCwJI1oN2upLDDwc{B{cW6pbHWg[I9{\SCvZXHzeZJm\CC3cDD0c{A5KGi{cx?= NH;2[lc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKxNVQ5OCd-MkmyNVE1QDB:L3G+
PC3 NX;kOVhHSW62aYT1cY9zKGG|c3H5 MXKzNEBu\y:tZx?= NHXFNotCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgfIVvd2e{YX\0JI1wfXOnIH3v[IVtKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhfHWvb4Kg[5Jwf3SqIHH0JFMxKG2pL3vnMEBxdyCkaXSgbY4heHKnc3XuZ4Uhd2ZiMT3hcYlvd2KnborveJJq[XqxbHW= MoKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MUG0PFAoRjJ7MkGxOFgxRC:jPh?=
PC3 MoLYRY51cXS3bX;yJIF{e2G7 M1\CVFYxKG2pL3vn MULBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNieHXuc4dz[W[2IH3veZNmKG2xZHXsJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiZ4Lve5RpKGG2IE[wJI1oN2upLDDwc{BjcWRiaX6gdJJme2WwY3Wgc4YhOS2jbXnuc4JmdnqxdILpZZpwdGV? NVzP[3Z2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNVE1QDBpPkK5NlEyPDhyPD;hQi=>
HEK293 NHLhWWFHfW6ldHnvckBie3OjeR?= NXPKe5B5OzBibXnudy=> M3noc2lvcGmkaYTpc44hd2ZibWTPVmMzKGmwIFjFT|I6OyClZXzsd{B2e2mwZzDHV3QufGGpZ3XkJHM3UzFib4KgRYt1OSCjczDzeYJ{fHKjdHWgZYZ1\XJiM{CgcYlveyCkeTDpcY12dm:kbH;0eIlv\yCjc4PhfUwhUUN3ME2wMlAy|ryP Mo\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MUG0PFAoRjJ7MkGxOFgxRC:jPh?=
SW620 NVLMdlFjTnWwY4Tpc44h[XO|YYm= Mnn5NlAhdWdxa3e= NGXBW|ZRd3SnboTpZZRqd25ib3[gbZJqdm:2ZXPhck1qdmS3Y3XkJJR2dW:{IILl[5Jme3Orb36gZYdicW6|dDDoeY1idiCVV{[yNEBk\WyuczD4[Y5w\3KjZoTl[EBqdiCrbX31co9kd22ycn;tbZNm\CCvb4Xz[UBifCB{MDDt[{9s\yxicH:gdYQh[WSvaX7pd5RmemWmIH;uJIRigXNiMjD0c{A1KG:oIIfl[YttgSCleXPs[S=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJzMUS4NEc,Ojl{MUG0PFA9N2F-
SJ-GBM2 NXjwWHdweUiWUzDhd5NigQ>? M4m3PZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NXLVU5RuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MVfxTHRUKGG|c3H5 M4HC[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MluzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC MlrWdWhVWyCjc4PhfS=> M4XWU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NG[1[Vk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NWr5N4d3eUiWUzDhd5NigQ>? NFTRO5ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= M4rrOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MYjxTHRUKGG|c3H5 MnvadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= M13SSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 NVPkboZMeUiWUzDhd5NigQ>? MoTDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= M1vLXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) M3;neJFJXFNiYYPzZZk> NWHQfmd4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NGjPXmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 MXHxTHRUKGG|c3H5 MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NYfBXIlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 Mn3vdWhVWyCjc4PhfS=> NXvL[YpOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl? MlG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 M2i2PZFJXFNiYYPzZZk> NYPxR4kyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? NGDrU3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY M3fv[JFJXFNiYYPzZZk> M1\3bpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGRCV1liY3XscJM> NEPObHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 MnPFdWhVWyCjc4PhfS=> MnX1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>? M3;rbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS MmiydWhVWyCjc4PhfS=> NGrINlJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN? NVLySpdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 MWjxTHRUKGG|c3H5 MojZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> M3f4N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NYHNdVhDeUiWUzDhd5NigQ>? NILLOFlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=> M4DTfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 M2CzbJFJXFNiYYPzZZk> NF;VVpNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{ M33PSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30 M37YSZFJXFNiYYPzZZk> NGntUFJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{ NHL0NVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH NFXJd2RyUFSVIHHzd4F6 MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{ MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Assay
Methods Test Index PMID
Western blot p-S6K / S6K / p-4E-BP1 / E7 / E6 / p53 ; p-mTOR 28115701 24262658
In vivo Ku0063794 inhibits tumor growth and mTOR signaling in a preclinical renal cell carcinoma model. However, Ku0063794 was not more effective than temsirolimus in the animal study. A possible explanation for lack of greater activity in vivo for Ku0063794 is that temsirolimus has important effects on the tumor microenvironment. Temsirolimus decreased angiogenesis in the xenograft tumors while Ku0063794 did not. Temsirolimus treated tumors expressed less VEGF and PDGF than Ku0063794 treated tumors, thus stimulating less angiogenesis[2].

Protocol (from reference)

Kinase Assay:

[1]

  • mTOR complexes kinase assays:

    HEK-293 cells are freshly lysed in Hepes lysis buffer. Lysate (1-4 mg) is pre-cleared by incubating with 5-20 μL of Protein G-Sepharose conjugated to pre-immune IgG. The lysate extracts are then incubated with 5-20 μL of Protein G-Sepharose conjugated to 5-20 μg of either anti-Rictor or anti-Raptor antibody, or pre-immune IgG. All antibodies are covalently conjugated to Protein G-Sepharose. Immunoprecipitations are carried out for 1 hour at 4 °C on a vibrating platform. The immunoprecipitates are washed four times with Hepes lysis buffer, followed by two washes with Hepes kinase buffer. For Raptor immunoprecipitates used for phosphorylating S6K1, for the initial two wash steps the buffer includes 0.5 M NaCl to ensure optimal kinase activity. GST-Akt1 is isolated from serum-deprived HEK-293 cells incubated with PI-103 (1 μM for 1 hour). GST-S6K1 is purified from serum-deprived HEK-293 cells incubated with rapamycin (0.1 μM for 1 hour). mTOR reactions are initiated by adding 0.1 mM ATP and 10 mM MgCl2 in the presence of various concentrations of KU-0063794 and GST-Akt1 (0.5 μg) or GST-S6K1 (0.5 μg). Reaction are carried out for 30 minutes at 30 °C on a vibrating platform and stopped by addition of SDS sample buffer. Reaction mixtures are then filtered through a 0.22-μm-poresize Spin-X filter and samples are subjected to electrophoresis and immunoblot analysis with the indicated antibodies.

Cell Research:

[1]

  • Cell lines: Wild-type and mLST8 deficient MEFs
  • Concentrations: Dissolved in DMSO, final concentration ~3 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method:

    Cells are treated with KU-0063794 for 24, 48, and 72 hours, and the medium is changed every 24 hours with freshly dissolved KU-0063794. For the measurement of cell growth, cells are washed once with PBS, and fixed in 4% (v/v) paraformaldehyde in PBS for 15 minutes. After washing once with water, the cells are stained with 0.1% Crystal Violet in 10% ethanol for 20 minutes and washed three times with water. Crystal Violet is extracted from cells with 0.5 mL of 10% (v/v) ethanoic (acetic) acid for 20 minutes. The eluate is then diluted 1:10 in water and absorbance at 590 nm is quantified. For the assessment of cell cycle distribution, cells are harvested by trypsinization, washed once in PBS, and re-suspended in ice-cold aq. 70% (v/v) ethanol. Cells are washed twice in PBS plus 1% (w/v) BSA and stained for 20 minutes in PBS plus 0.1% (v/v) Triton X-100 containing 50 g/mL propidium iodide and 50 g/mL RNase A. The DNA content of cells is determined using a FACSCalibur flow cytometer and CellQuest software. Red fluorescence (585 nm) is acquired on a linear scale, and pulse width analysis is used to exclude doublets. Cell-cycle distribution is determined using FlowJo software.

Animal Research:

[2]

  • Animal Models: Nu/Nu nude mice
  • Dosages: 8 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 465.54
Formula

C25H31N5O4

CAS No. 938440-64-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CN(CC(O1)C)C2=NC3=C(C=CC(=N3)C4=CC(=C(C=C4)OC)CO)C(=N2)N5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy KU-0063794 | KU-0063794 supplier | purchase KU-0063794 | KU-0063794 cost | KU-0063794 manufacturer | order KU-0063794 | KU-0063794 distributor